Altimmune Commences Enrollment In Phase 1 Clinical Trial Of AdCOVID™ — A Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate Intranasal administration targets the virus at its point of entry and in a [….]
5 Questions with Doug White, Senior Vice President, Devices Business Unit Head, Emergent BioSolutions
Doug White joined Emergent in 2017 and serves as head of the devices business unit. He previously served as vice president and general manager of Molecular Diagnostics & Women’s Health at Becton Dickenson Diagnostics. Before joining Becton Dickenson Diagnostics, he was chief executive officer of OpGen Inc.